These risks, as well as other risks associated with the combination, will be more fully discussed in the proxy statement/prospectus that will be included in the registration statement that will be filed with the SEC in connection with the proposed transaction. Dr. Kaplin, the prior founder and chief of the Neuropsychiatric CNS Autoimmune Consultation Clinic, at the Johns Hopkins Multiple Sclerosis Center of Excellence, and an assistant professor of psychiatry and behavioral sciences at the Johns Hopkins University School of Medicine, has consulted with multiple hospitals, biotechnology companies and non-profit organizations on medical and development matters. The combined company is … Good afternoon and thank you for joining this Akers Biosciences Conference Call to discuss our merger agreement with MyMD Pharmaceuticals. Important Additional Information Will be Filed with the SEC. ● Immunotherapies focused on age-related disorders and autoimmune diseases entering Phase 2 clinical trials, ● Lead molecule MYMD-1 inhibits production of tumor necrosis factor alpha (TNF-α), a cell signaling protein involved in systemic inflammation, in preclinical studies, ● Entered into Securities Purchase Agreement for $18M private placement of common stock and warrants priced at-the-market under Nasdaq Rules, BALTIMORE & THOROFARE, N.J.--(BUSINESS WIRE)--MyMD Pharmaceuticals, Inc. (“MyMD”) and Akers Biosciences, Inc. (“Akers”) (NASDAQ: AKER) today jointly announced that they have entered into a definitive merger agreement. Puedes cambiar tus opciones en cualquier momento visitando Tus controles de privacidad. By John George – Senior Reporter, Philadelphia Business Journal . firm. … November 12, 2020. In addition, investors and shareholders will be able to obtain free copies of the proxy statement, prospectus and other documents filed by Akers with the SEC by contacting Investor Relations by mail at Akers Biosciences, Inc., Attn: Investor Relations, 201 Grove Road, West Deptford, NJ 08086. 201-465-8019 Under a definitive merger agreement, the combined company will be known as MyMD Pharmaceuticals Inc. and keep Akers’ place on the Nasdaq under the new ticker symbol “MYMD.” The combined company will focus on developing … Certain statements contained in this communication regarding matters that are not historical facts are forward-looking statements within the meaning of Section 21E of the Securities and Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, known as the PSLRA. New factors emerge from time to time and it is not possible for us to predict all such factors, nor can we assess the impact of each such factor on the business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. 10,835,523 B2, titled "Method of Regulating Tumor Necrosis Factor-Alpha (TNF-α) for Treating Cancers, Autoimmune Disorders, and Other Disorders Associated with Chronic Inflammation" by the United States Patent & Trademark Office … : 001-36268 . Akers Biosciences, Inc. (Nasdaq: AKER), today announced that its proposed merger partner MyMD Pharmaceuticals, Inc. ("MyMD") was issued US Pat. The companies plan to hold a video conference for investors on Wednesday, November 18, 2020 at 4:15 p.m. Dr. Chapman is the founder and CEO of Chapman Pharmaceutical Consulting Inc. and will bring extensive experience working with biotechnology companies in the design of clinical trial protocols, conducting clinical trials and advising on regulatory and medical affairs. AKERS URGES INVESTORS AND STOCKHOLDERS TO READ THESE MATERIALS CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT AKERS, THE PROPOSED TRANSACTION AND RELATED MATTERS. Reflecting on the rationale for the merger, Chris Schreiber, Executive Chairman and President of Akers, stated, "We are excited about this strategic opportunity to focus on MyMD’s promising clinical development program and worldwide patent position. The company aims to raise $18 million by issuing9,765,933 common stock shares and accompanying warrants up to 9,765,933 of common stock shares. The note bears interest at 5% per annum, has a maturity date of April 15, 2022 and is secured by a first lien on MyMD's assets. Fortune features an announcement of the MyMD Pharmaceuticals and Akers Biosciences merger. Contact our support team if you have any enquiries about any of our products. Para permitir a Verizon Media y a nuestros socios procesar tus datos personales, selecciona 'Acepto' o selecciona 'Gestionar ajustes' para obtener más información y para gestionar tus opciones, entre ellas, oponerte a que los socios procesen tus datos personales para sus propios intereses legítimos. Upon closing the transaction, the … MyMD Pharmaceuticals Inc. and Akers Biosciences Inc. said that they have entered into a definitive merger agreement. No. Akers Biosciences, Inc., today announced that its proposed merger partner MyMD Pharmaceuticals, Inc. was issued US Pat. Upon closing the transaction, the combined company is expected to be renamed MyMD Pharmaceuticals, Inc. and remain listed on the Nasdaq under the new ticker symbol “MYMD.” BALTIMORE & THOROFARE, N.J.--(BUSINESS WIRE)--MyMD Pharmaceuticals, Inc. and Akers Biosciences, Inc. (NASDAQ: AKER) today jointly announced that they have entered into a definitive merger agreement. For more information, visit www.mymd.com. AKERS MERGER INVESTIGATION: HALPER SADEH LLP ANNOUNCES INVESTIGATION INTO WHETHER THE MERGER OF AKERS BIOSCIENCES, INC. IS FAIR TO SHAREHOLDERS; INVESTORS ARE ENCOURAGED TO CONTACT THE FIRM – AKER . Concurrently with the execution of the merger agreement with MyMD, Akers entered into a securities purchase agreement with certain accredited investors to raise $18 million through the issuance of up to 9,765,933 shares of common stock (or common stock equivalents) and accompanying warrants to purchase an aggregate of up to 9,765,933 shares of common stock at $1.85 per share of common stock and accompanying warrant. As beforehand introduced, Akers Biosciences and MyMD Pharmaceuticals introduced a definitive merger settlement, whereby the 2 corporations will be a part of as one to give attention to growing and commercializing MyMD’s novel immunotherapy pipeline property. Akers and MyMD undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent required by law. Upon closing the transaction, the combined company is expected to be renamed MyMD Pharmaceuticals, Inc. and remain listed on the Nasdaq under the new ticker … Akers Biosciences, Inc. (Nasdaq: AKER), today announced that its proposed merger partner MyMD Pharmaceuticals, Inc. ("MyMD") was issued US … ET to provide additional context on the integrated company, the clinical pipeline and drug development plan, and the commercial potential of the targeted indications. As previously announced, Akers Biosciences and MyMD Pharmaceuticals announced a definitive merger agreement, whereby the two companies will join as one to focus on developing and commercializing MyMD’s novel immunotherapy pipeline assets. These documents can be obtained free of charge from the sources indicated above. Investors and stockholders are urged to read the proxy statement, prospectus and the other relevant materials when they become available before making any voting or investment decision with respect to the proposed transaction. Pursuant to the merger agreement, at the close of the merger, Akers stockholders will own approximately 20% of the combined company. 12.11.2020 - MyMD Pharmaceuticals, Inc. (“MyMD”) and Akers Biosciences, Inc. (“Akers”) (NASDAQ: AKER) today jointly announced that they have entered into a definitive merger … 12:10PM : Moore Kuehn Encourages CGIX, AKER, TGC and DNKN Investors to Contact Law Firm . The warrants are immediately exercisable at an exercise price of $2.06 per share, with an expiration date of five and one-half years after the date of issuance. MyMD Pharmaceuticals, Inc. ("MyMD") and Akers Biosciences, Inc. ("Akers") (NASDAQ: AKER) jointly announced a definitive merger agreement last week. No public offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended. Akers Biosciences' stock soars 29% on merger deal. Cautionary Statement Regarding Forward-Looking Statements. (RTTNews) - MyMD Pharmaceuticals Inc. and Akers Biosciences Inc. (AKER) said that they have entered into a definitive merger agreement. of the Securities Exchange Act of 1934. The company’s stock price has collected 20.97% of gains in the last five trading sessions. MyMD Pharmaceuticals, Inc. ("MyMD") and Akers Biosciences, Inc. ("Akers") (NASDAQ: AKER) jointly announced a definitive merger agreement last week. The companies plan to hold a video conference for investors on Wednesday, November 18, 2020 at 4:15 p.m. (RTTNews) - MyMD Pharmaceuticals Inc. and Akers Biosciences Inc. (AKER) said that they have entered into a definitive merger agreement. The combined company will be led by Chris Chapman, M.D., who will become President and Chief Medical Officer of MyMD, and Adam Kaplin, M.D., who will become Chief Scientific Officer of MyMD, and is planned to be headquartered in Baltimore, Maryland. AKERS BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Akers Biosciences, Inc. - AKER Business Wire NEW ORLEANS -- … BALTIMORE & THOROFARE, N.J.--(BUSINESS WIRE)-- MyMD Pharmaceuticals, Inc. (“MyMD”) and Akers Biosciences, Inc. (AKER) (“Akers”) today jointly announced that they have entered into a definitive merger agreement. Additional information regarding these persons and their interests in the transaction will be included in the proxy statement relating to the transaction when it is filed with the SEC. brett@haydenir.com Akers Biosciences, Inc. engages in the development, manufacture, and supply of screening and testing products. No. Edited Transcript of. MYMD-1 has been shown to be effective in regulating the immune system from causing age-related diseases in preclinical studies and MyMD believes that it is the first oral small molecule regulator of tumor necrosis factor alpha (TNF-α) capable of crossing the blood-brain barrier. Concurrently with the execution of the merger agreement with MyMD, Akers … www.antennagroup.com, https://www.webcaster4.com/Webcast/Page/2584/38815, Participant Dial In: Toll Free: 877-407-0778; International: 201-689-8565. The combined company will be led by Chris Chapman, who will become President and Chief … Forward-looking statements included in this release are based on information available to Akers and MyMD as of the date of this release. Thorofare pharma firm Akers in merger with Md. Información en tiempo real sobre las acciones de Akers Biosciences (AKER) en bolsa, incluyendo precio, gráficos, análisis técnico, datos históricos y mucho más. Such forward-looking statements are based on our expectations and involve risks and uncertainties; consequently, actual results may differ materially from those expressed or implied in the statements due to a number of factors, including, but not limited to, risks relating to the completion of the merger, including the need for stockholder approval and the satisfaction of closing conditions; Aker’s inability to consummate the private placement; the cash balances of the combined company following the closing of the merger; the ability of Akers to remain listed on the Nasdaq Capital Market in connection with the merger; and expected merger-related cash outlays, including the timing and amount of those outlays. A Phase 1 study on MYMD-1 has been completed, with plans to begin two Phase 2 clinical trials in Q1 2021 and additional Phase 2 clinical trials throughout 2021. Call: (856) 848-8698. NEW YORK, February 11, 2021 – Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of Akers Biosciences, Inc. (NASDAQ: AKER) breached their fiduciary duties or violated the federal securities laws in connection with the company’s acquisition by MyMD Pharmaceuticals, Inc. Yahoo forma parte de Verizon Media. Under an agreement with the investors, the Company is required to file a registration statement with the Securities and Exchange Commission covering the resale of the shares of common stock to be issued to the investors and to use best efforts to have the registration statement declared effective as promptly as practical thereafter. Nov 12, 2020 Updated Nov 12, 2020, 9:10pm EST. We use words such as "anticipates," "believes," "plans," "expects," "projects," "future," "intends," "may," "will," "should," "could," "estimates," "predicts," "potential," "continue," "guidance," and similar expressions to identify these forward-looking statements that are intended to be covered by the safe-harbor provisions of the PSLRA. In connection with the definitive merger agreement, Akers agreed to loan MyMD up to $3 million pursuant to a secured promissory note. MyMD Pharmaceuticals, Inc. ("MyMD") and Akers Biosciences, Inc. ("Akers") (NASDAQ: AKER) jointly announced a definitive merger agreement last week. BALTIMORE, MD. The mechanism of action for MYMD-1 involves shutting down the production of TNF-α, offering the potential to reshape clinical guidelines and treatment approaches for aging and a number of autoimmune diseases including diabetes, rheumatoid arthritis and multiple sclerosis. AGREEMENT AND PLAN OF MERGER AND REORGANIZATION . MyMD Pharmaceuticals, Inc. ("MyMD") and Akers Biosciences, Inc. ("Akers") (NASDAQ: AKER) today jointly announced that they have entered into a definitive merger agreement. This communication shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. November 12, 2020. Aker's Biosciences and MyMD Pharmaceuticals Sign Definitive Merger Agreement; Akers Shareholders To Own ~20% Of Combined Co., MyMD Shareholders To Own ~80% Immunotherapies focused on age-related disorders and autoimmune diseases entering Phase 2 clinical trials Lead molecule MYMD-1 inhibits production of tumor necrosis factor alpha (TNF-α), a cell Akers Biosciences Inc., a Thorofare-based pharmaceutical company, is merging with MyMD Pharmaceuticals, a Baltimore-based company, the two announced this week. According to a statement issued by the companies this week, MyMD Pharmaceuticals is merging with Akers Biosciences, a publicly traded company based in West Deptford, New Jersey.Going forward, the combined … 646-536-7331 The offer and sale of the foregoing securities are being made in a transaction not involving a public offering and have not been registered under the Securities Act of 1933, as amended (the "Securities Act"), or applicable state securities laws. MYMD-1 is being developed to treat autoimmune diseases, including those currently treated with TNF-α blocking drugs, and aging and longevity. Akers Biosciences Inc. (NASDAQ:AKER) went up by 18.97% from its latest closing price compared to the recent 1-year high of $8.85. Mymd Pharmaceuticals Inc., the privately held developer of a synthetic derivative of tobacco alkaloids for the potential treatment of autoimmune diseases and age-related disorders, will soon list on Nasdaq via its acquisition of former point-of-care testing company Akers Biosciences Inc., shares of which (NASDAQ:AKER) climbed 29.1% to $2.22 on Nov. 12. In connection with the definitive merger agreement, Akers agreed to loan MyMD up to $3 million pursuant to a secured promissory note. In premise to merger deal, Akers Biosciences, Inc. (AKER) entered into a securities purchase agreementwith certain accredited investors. 03:55PM : RM LAW Announces Investigation of Akers Biosciences, Inc. PR Newswire. Akers Biosciences is pursuing rapid development and manufacturing of a COVID-19 vaccine candidate in collaboration with Premas Biotech PVT Ltd. MyMD is a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms. Looking forward, MyMD intends to also continue to develop its second asset, SUPERA-1R, a drug platform based on a patent-protected, synthetic derivative of cannabidiol (CBD) that seeks to target key cannabinoid receptors. Findings of study published in PLOS One found a highly significant correlation between temperature and the rate of increase in COVID-19 An estimated one degree increase in temperature is associated with a 1% decrease in COVID-19 transmissions, and a one degree decrease in temperature is associated with a 3.7% increase in transmission rate … ET to provide additional context on the integrated company, the clinical pipeline and drug … www.haydenir.com, Media Contact: Under a definitive merger agreement, the combined company will be known as MyMD Pharmaceuticals Inc. Akers Biosciences and MyMD Pharmaceuticals Enter Merger . BALTIMORE & THOROFARE, N.J.--(BUSINESS WIRE)-- MyMD Pharmaceuticals, Inc. (“MyMD”) and Akers Biosciences, Inc. (AKER) (“Akers”) today jointly announced that they have entered into a definitive merger agreement. SUPERA-1R is a drug platform based on a novel (patent pending) synthetic derivative of cannabidiol (CBD) that targets numerous key receptors including CB2 and opioid receptors and inhibits monoamine oxidase. The merger is expected to close in the first half of 2021, subject to the approval of Akers’ shareholders at a special shareholder meeting, as well as other customary closing conditions. 18 Nov 2020 REMINDER: Akers Biosciences Schedules Conference Call to Discuss Merger with MyMD Pharmaceuticals. Information about Akers’ directors and executive officers is included in Akers’ Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC on March 25, 2020, as amended on October 21, 2020, and the proxy statement for Akers’ 2020 annual meeting of stockholders, filed with the SEC on July 29, 2020. “Over the last seven years, MyMD has advanced its robust drug development program, achieving very encouraging preclinical and Phase 1 clinical data,” said Chris Chapman, M.D., Chief Medical Officer of MyMD. Through this transaction, the company will be committed to delivering novel, multi-indication platform drugs designed to extend healthy lifespan and treat the source of chronic autoimmune diseases.